Stockreport

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 [Yahoo! Finance]

Enanta Pharmaceuticals, Inc.  (ENTA) 
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.enanta.com/investor-overview
PDF dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-pro [Read more]